Cargando…

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

INTRODUCTION: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has demonstrated clinical benefits in phase 3 trials. We report results from a real-world study (BRIO) to assess the effectiveness of ivacaftor in people with cystic fibrosis (pwCF) in France. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hubert, Dominique, Marguet, Christophe, Benichou, Jacques, DeSouza, Cynthia, Payen-Champenois, Catherine, Kinnman, Nils, Chandarana, Keval, Munck, Anne, Fajac, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589905/ https://www.ncbi.nlm.nih.gov/pubmed/34101145 http://dx.doi.org/10.1007/s41030-021-00158-5

Ejemplares similares

Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation
por: Kerem, Eitan, et al.
Publicado: (2021)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
por: Duckers, Jamie, et al.
Publicado: (2021)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
por: Bell, Scott C., et al.
Publicado: (2019)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Profiling the response to lumacaftor‐ivacaftor in children with cystic between fibrosis and new insight from a French‐Italian real‐life cohort
por: Cornet, Matthieu, et al.
Publicado: (2022)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
por: Fajac, Isabelle, et al.
Publicado: (2021)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
por: Shiferaw, Dejene, et al.
Publicado: (2019)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
por: Faruqi, Shoaib, et al.
Publicado: (2016)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
por: Colombo, C., et al.
Publicado: (2021)

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
por: King, Susannah J., et al.
Publicado: (2021)

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)

Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
por: Al‐Din, Yasmin, et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis
por: Vadagam, Pratyusha, et al.
Publicado: (2018)

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients
por: Gostelie, Romee, et al.
Publicado: (2020)

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
Publicado: (2019)

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
por: Kutney, Katherine, et al.
Publicado: (2019)

Ivacaftor for the Treatment of Cystic Fibrosis Coexisting with Trisomy 21: A Case Report
por: Charbek, Edward, et al.
Publicado: (2019)

383: Cystic fibrosis macrophage function after elexacaftor/tezacaftor/ivacaftor initiation
por: Zhang, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pqjacjkdbkrjhlsh7t3vpd6l6d